Innovation in bone healing and tissue repair

Kuros develops products based on a number of proprietary technologies. These products are based on either a synthetic-based technology platform or a fibrin-based technology platform.

The surface science technology in the MagnetOs products allows the generation of new orthopedic materials with innovative and proprietary surface properties that stimulate the body to form bone. It has been demonstrated that these materials are as effective as autologous bone graft.

The synthetic cross-linking technology is based on cross-linking chemistry that allows the polymerization of many molecule types to form useful biomaterials. This technology is very flexible and allows its use in products with a wide range of characteristics and for varied applications. It exhibits good biocompatibility, can be physically linked with biologics and can be polymerized in-situ (i.e. they form and stay where needed), creating a perfect shape matching and biologically active material.

The fibrin based technology platform uses a unique biologic linker and release mechanism (the Kuros TG Hook Technology) to combine the base products with biologics. This technology permits the active ingredient to be held within the product until its targeted local release during the natural healing process. Accordingly, the fibrin-based technology platform permits product designs that are expected to be minimally invasive and to allow relatively low dosage of biologics to induce growth of tissue or bone where it is needed, thereby increasing both efficacy and safety and potentially reducing cost compared to existing products.

In addition Kuros has immune-modulating technologies that it is progressing in collaboration with partners.

Both technologies  can be used  to develop products with a wide range of physical and biological characteristics for a range of applications. Both technology platforms exhibit good biocompatibility, can be physically linked with biologics and can be polymerized in-situ (i.e. they form and stay where needed), creating a perfect shape matching and biologically active material. The primary growth factor incorporating technology is called TG-Hook technology.

 In addition Kuros has immune-modulating technologies that it is progressing in collaboration with partners.

 

Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 (0)44 200 56 00   Fax: +41 (0)44 200 56 01   Email: info@kuros.ch

About Kuros

  1. Overview
  2. Management
  3. Board

Products

  1. Pipeline
  2. Orthobiologics
    Fracture repair
    KUR-111
    KUR-113
    Spinal fusion
    KUR-113
    Solitary Bone Cysts
    KUR-112
  3. Sealants
    Neuroseal (KUR-023)

Technologies

  1. Overview
  2. Fibrin-based
  3. Synthetic-based
  4. Immune modulation
  5. Publications

Partnerships

  1. Collaborations
  2. Business development

Investors

  1. Share price
  2. Regulatory filings
  3. Reports & presentations
  4. Calendar
  5. Corporate governance
  6. Stay informed

News

  1. Press releases
  2. Conferences & Events

Contact

  1. Location
Overview

Kuros develops products based on a number of proprietary technologies. These products are based on either a synthetic-based technology platform or a fibrin-based technology platform.

The surface science technology in the MagnetOs products allows the generation of new orthopedic materials with innovative and proprietary surface properties that stimulate the body to form bone. It has been demonstrated that these materials are as effective as autologous bone graft.

The synthetic cross-linking technology is based on cross-linking chemistry that allows the polymerization of many molecule types to form useful biomaterials. This technology is very flexible and allows its use in products with a wide range of characteristics and for varied applications. It exhibits good biocompatibility, can be physically linked with biologics and can be polymerized in-situ (i.e. they form and stay where needed), creating a perfect shape matching and biologically active material.

The fibrin based technology platform uses a unique biologic linker and release mechanism (the Kuros TG Hook Technology) to combine the base products with biologics. This technology permits the active ingredient to be held within the product until its targeted local release during the natural healing process. Accordingly, the fibrin-based technology platform permits product designs that are expected to be minimally invasive and to allow relatively low dosage of biologics to induce growth of tissue or bone where it is needed, thereby increasing both efficacy and safety and potentially reducing cost compared to existing products.

In addition Kuros has immune-modulating technologies that it is progressing in collaboration with partners.

Both technologies  can be used  to develop products with a wide range of physical and biological characteristics for a range of applications. Both technology platforms exhibit good biocompatibility, can be physically linked with biologics and can be polymerized in-situ (i.e. they form and stay where needed), creating a perfect shape matching and biologically active material. The primary growth factor incorporating technology is called TG-Hook technology.

 In addition Kuros has immune-modulating technologies that it is progressing in collaboration with partners.